- Home
- WHF vs TLSI Comparison
WHF vs TLSI Comparison
Compare WHF & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHF
- TLSI
- Stock Information
- Founded
- WHF 2011
- TLSI 2010
- Country
- WHF United States
- TLSI United States
- Employees
- WHF N/A
- TLSI N/A
- Industry
- WHF Finance Companies
- TLSI Medical Specialities
- Sector
- WHF Finance
- TLSI Health Care
- Exchange
- WHF Nasdaq
- TLSI Nasdaq
- Market Cap
- WHF 207.1M
- TLSI 204.0M
- IPO Year
- WHF 2012
- TLSI N/A
- Fundamental
- Price
- WHF $9.02
- TLSI $4.56
- Analyst Decision
- WHF Sell
- TLSI Strong Buy
- Analyst Count
- WHF 4
- TLSI 5
- Target Price
- WHF $10.83
- TLSI $10.90
- AVG Volume (30 Days)
- WHF 80.4K
- TLSI 133.1K
- Earning Date
- WHF 08-07-2025
- TLSI 08-13-2025
- Dividend Yield
- WHF 19.79%
- TLSI N/A
- EPS Growth
- WHF N/A
- TLSI N/A
- EPS
- WHF 0.39
- TLSI N/A
- Revenue
- WHF $86,143,000.00
- TLSI $32,141,000.00
- Revenue This Year
- WHF N/A
- TLSI $55.39
- Revenue Next Year
- WHF N/A
- TLSI $54.89
- P/E Ratio
- WHF $22.92
- TLSI N/A
- Revenue Growth
- WHF N/A
- TLSI 46.20
- 52 Week Low
- WHF $8.44
- TLSI $3.50
- 52 Week High
- WHF $12.42
- TLSI $6.04
- Technical
- Relative Strength Index (RSI)
- WHF 52.23
- TLSI 39.21
- Support Level
- WHF $8.89
- TLSI $4.41
- Resistance Level
- WHF $9.05
- TLSI $4.73
- Average True Range (ATR)
- WHF 0.15
- TLSI 0.22
- MACD
- WHF 0.02
- TLSI -0.02
- Stochastic Oscillator
- WHF 45.83
- TLSI 18.99
About WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.